Tamoxifen and pregnancy: an absolute contraindication?
- 57 Downloads
Breast cancer is the most common malignancy among young women of reproductive age. Adjuvant treatment with tamoxifen reduces the risk of recurrence in hormone-sensitive breast cancer. However, the use of tamoxifen is considered contraindicated during pregnancy, because of a limited number of case reports demonstrating potential adverse effects on the fetus. The objective of this report is to give a more broad overview of the available data on the effect of tamoxifen exposure during pregnancy.
A literature review was performed using PubMed and the databases of the Netherlands Pharmacovigilance Centre Lareb and of the International Network on Cancer, Infertility, and Pregnancy.
A total of 238 cases of tamoxifen use during pregnancy were found. Of the 167 pregnancies with known outcome, 21 were complicated by an abnormal fetal development. The malformations described were non-specific and the majority of cases concerned healthy infants despite exposure to tamoxifen.
There seems to be an increased risk of fetal abnormalities when taking tamoxifen during pregnancy (12.6% in contrast to 3.9% in the general population), but the evidence is limited and no causal relationship could be established. The possible disadvantage of postponing or discontinuing tamoxifen for the maternal prognosis is unclear. Patients should be counseled about the use of tamoxifen during pregnancy instead of presenting it as being absolutely contraindicated.
KeywordsTamoxifen Breast cancer Pregnancy Teratogenicity Fetal toxicity
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
Human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.The Netherlands Cancer Registry, the Netherlands Comprehensive Cancer Organisation (IKNL). https://www.cijfersoverkanker.nl/home-36.html. Accessed 15 Oct 2018
- 2.Breast Cancer, Dutch National Guideline, IKNL, version 1.0 (2018) https://richtlijnendatabase.nl/en/richtlijn/breast_cancer/breast_cancer.html. Accessed 15 Oct 2018
- 12.Ruiz-Velasco V, Rosas-Arceo J, Matute MM (1979) Chemical inducers of ovulation: comparative results. Int J Fertil 24:61–64Google Scholar
- 17.Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M et al (2005) Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: Implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56(suppl 1):10–20CrossRefGoogle Scholar
- 21.Zhou MH, Han GZ, Chu YH (1991) Effects of antiestrogenic drug tamoxifen on human placental secretion of progesterone and human chorionic gonadotropin during early gestation. Yao Xue Xue Bao 26(11):801–804Google Scholar
- 24.Weiss G (2000) Endocrinology of parturition. J Clin Endocrinol Metab 85(12):4421–4425Google Scholar
- 25.Product information. Nolvadex. Zeneca Pharmaceuticals (1997)Google Scholar
- 36.Harper MJK (1992) Agents with antifertility effects during preimplantation stages of pregnancy. In: Moghissi KS, Hafez ESE (eds) Biology of mammalian fertilization and implantation. Charles C. Thomas, Springfield, pp 431–492Google Scholar
- 38.Grandvuillemin A, Rousseau T, Laurent N, Meyer F, Lebouvier M, Disson-Dautriche A (2009) A case of sexual ambiguity under tamoxifen during pregnancy. Fund Clin Pharmacol 23(Suppl 1):37Google Scholar
- 46.Schönbeck U, Hindori-Mohangoo AD, Masurel N, Van der Pal-de Bruin KM (2015) TNO report: Congenital malformations in the Netherlands 2001–2013: Based on Netherlands Perinatal Registry. https://repository.tudelft.nl/view/tno/uuid%3A1879cf51-0f9e-4051-8829-296fdcad2847. Accessed 20 Dec 2018
- 48.Hershman DL, Shao T, Kushi LH, Buono D, Yann Tsai W, Fehrenbacher L, Kwan M, Lin Gomez S, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537CrossRefGoogle Scholar
- 49.Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer (POSITVE). http://clinicaltrials.gov/ct2/show/NCT02308085. Accessed 15 Oct 2018